OnCusp: Bing Yuan’s newco to provide bridge from innovation to MNC
Emerging Company Profile: OnCusp launches to license, develop early stage cancer therapies before out-licensing assets to MNCs
Former CStone and Merck & Co. dealmaker Bing Yuan and his OnCusp co-founders are using their early stage drug hunting skills to identify cancer assets from the U.S. and China that will appeal to MNCs, and guide them to POC before out-licensing.
OnCusp Therapeutics emerged from stealth on Tuesday with a $25 million seed round led by Sequoia Capital China and Biotrack Capital, and a focus on making deals to bring in innovative cancer therapies, including antibody-drug conjugates (ADCs) and multispecific therapies. ...